Precautions for four groups of people who should not take Anagrelide

Anagrelide is a drug used to treat essential thrombocythemia (ET) and other myeloproliferative diseases by inhibiting platelet production to control platelet levels. However, despite the clinically significant efficacy of anagrelide, not all patients are suitable for the drug.

First, anagrelide is not suitable for patients with severe heart disease. Anagrelide may cause cardiac side effects, especially with long-term use, including arrhythmias, myocardial ischemia and other problems. Therefore, patients with heart disease, hypertension, heart failure and other diseases should use anagrelide under the guidance of a doctor to avoid serious cardiovascular complications.

The second category of inapplicable groups is patients with severe liver dysfunction. Anagrelide is mainly metabolized by the liver. If liver function is damaged, the metabolic process of the drug may be affected, thereby increasing the toxicity of the drug or prolonging the action time of the drug in the body. Therefore, patients with hepatic insufficiency need to be particularly careful when using anagrelide, and adjust the drug dose or choose other drugs instead if necessary.

The third category of people who should not take anagrelide are pregnant women and lactating women. Anagrelide is a class C drug, which means it may pose a potential risk to the fetus, so pregnant women should avoid using anagrelide during pregnancy. In addition, because anagrelide may pass into the baby's body through breast milk, nursing mothers need to be cautious when using this drug. If use is necessary, it is recommended to evaluate the risks and benefits under the guidance of a doctor.

Finally, anagrelide is not suitable for use in patients with severe bleeding tendencies. Anagrelide treats thrombocytosis by inhibiting platelet production, which may increase the risk of bleeding. In patients with bleeding disorders or low platelet counts, use of anagrelide may result in serious bleeding complications and needs to be avoided or monitored closely.

Reference materials:https://go.drugbank.com/drugs/DB00261